Analyst Reco. ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
1.94 ^USD	-1.02%		-2.51%	-2.02%

14/03	Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	MT
13/03	ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	14/03	MT
Raymond James Adjusts ProQR Therapeutics' Price Target to $4 From $5, Keeps Outperform Rating	08/11	MT
Chardan Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $2	08/11	MT
Citigroup Adjusts ProQR Therapeutics' Price Target to $1.80 From $2.10, Keeps Neutral Rating	18/23/18	MT
Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating	24/23/24	MT
Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating	17/23/17	MT
HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating	30/23/30	MT
Raymond James Adjusts ProQR Therapeutics Price Target to $5 From $2, Maintains Outperform Rating	23/22/23	MT
Cantor Fitzgerald Upgrades ProQR Therapeutics to Overweight From Neutral, Adjusts Price Target to $5 From $0.80	22/22/22	MT
HC Wainwright Adjusts Price Target on ProQR Therapeutics to $1.50 From $2, Reiterates Buy Rating	15/22/15	MT
Cantor Fitzgerald Downgrades ProQR Therapeutics to Neutral From Overweight, Adjusts Price Target to $0.80 From $3.50	12/22/12	MT
Raymond James Upgrades ProQR Therapeutics to Outperform From Market Perform; Price Target is $2	12/22/12	MT
Chardan Research Downgrades ProQR Therapeutics to Neutral From Buy on Further Restructuring, Wind-Down of Inherited Retinal Disease Programs; $2 Price Target Removed	12/22/12	MT
HC Wainwright Lowers ProQR Therapeutics N.V's Price Target to $2 From $4, Buy Rating Kept	09/22/09	MT
Chardan Lowers Price Target for ProQR Therapeutics N.V to $2 From $2.50, Maintains Buy Rating	06/22/06	MT
Chardan Capital Adjusts Price Target for ProQR Therapeutics N.V to $2.50 From $8, Maintains Buy Rating	14/22/14	MT
JMP Securities Adjusts ProQR Therapeutics' Price Target to $5 from $8, Keeps Market Outperform Rating	14/22/14	MT
Citigroup Adjusts ProQR Therapeutics' Price Target to $1 From $1.70, Maintains Neutral Rating	15/22/15	MT
Chardan Adjusts Price Target on ProQR Therapeutics to $8 From $18, Maintains Buy Rating	14/22/14	MT
Citigroup Downgrades ProQR Therapeutics to Neutral From Buy, Sets $1.70 Price Target	14/22/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Analyst Reco.

Filters